BR112023002112A2 - Composto para direcionar e degradar proteínas, e método para preparar o mesmo e uso do mesmo - Google Patents

Composto para direcionar e degradar proteínas, e método para preparar o mesmo e uso do mesmo

Info

Publication number
BR112023002112A2
BR112023002112A2 BR112023002112A BR112023002112A BR112023002112A2 BR 112023002112 A2 BR112023002112 A2 BR 112023002112A2 BR 112023002112 A BR112023002112 A BR 112023002112A BR 112023002112 A BR112023002112 A BR 112023002112A BR 112023002112 A2 BR112023002112 A2 BR 112023002112A2
Authority
BR
Brazil
Prior art keywords
compound
targeting
preparing
same
irak4
Prior art date
Application number
BR112023002112A
Other languages
English (en)
Inventor
Feng Yan
Li Shiqiang
Original Assignee
Shanghai Leadingtac Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Leadingtac Pharmaceutical Co Ltd filed Critical Shanghai Leadingtac Pharmaceutical Co Ltd
Publication of BR112023002112A2 publication Critical patent/BR112023002112A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO PARA DIRECIONAR E DEGRADAR PROTEÍNAS, E MÉTODO PARA PREPARAR O MESMO E USO DO MESMO. A presente invenção fornece uma classe de compostos bifuncionais para direcionar e degradar uma proteína quinase IRAK4, uma composição farmacêutica e um método para preparar os mesmos. O composto da presente invenção pode não apenas inibir e/ou degradar eficazmente a proteína quinase IRAK4 nas células, mas pode também inibir eficazmente a produção de IL-6 por células imunes e tem boa seletividade de degradação. O composto pode ser usado na preparação de um fármaco para tratar e/ou prevenir doenças ou condições mediadas por IRAK4 relacionadas, como câncer, doenças imunológicas e doenças inflamatórias.
BR112023002112A 2020-08-05 2021-08-05 Composto para direcionar e degradar proteínas, e método para preparar o mesmo e uso do mesmo BR112023002112A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010785541 2020-08-05
CN202011513669 2020-12-18
PCT/CN2021/110990 WO2022028547A1 (zh) 2020-08-05 2021-08-05 靶向蛋白降解化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
BR112023002112A2 true BR112023002112A2 (pt) 2023-04-18

Family

ID=80117051

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002112A BR112023002112A2 (pt) 2020-08-05 2021-08-05 Composto para direcionar e degradar proteínas, e método para preparar o mesmo e uso do mesmo

Country Status (11)

Country Link
US (1) US20230234936A1 (pt)
EP (1) EP4194457A1 (pt)
JP (1) JP2023530848A (pt)
KR (1) KR20230050375A (pt)
CN (2) CN115244053B (pt)
AU (1) AU2021323304A1 (pt)
BR (1) BR112023002112A2 (pt)
CA (1) CA3188258A1 (pt)
MX (1) MX2023001566A (pt)
TW (1) TWI833104B (pt)
WO (1) WO2022028547A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115710274A (zh) * 2021-08-23 2023-02-24 上海领泰生物医药科技有限公司 Irak4降解剂及其制备方法和应用
WO2024094190A1 (zh) * 2022-11-04 2024-05-10 上海领泰生物医药科技有限公司 Irak4降解剂及其用途
CN117024413B (zh) * 2023-10-07 2024-01-09 天津匠新致成科技有限公司 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614134D0 (en) * 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
MX2019009046A (es) * 2017-01-31 2019-10-30 Arvinas Operations Inc Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
AU2018392716A1 (en) 2017-12-20 2020-06-18 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
WO2019160915A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
JP2022516401A (ja) 2018-11-30 2022-02-28 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用

Also Published As

Publication number Publication date
TW202210470A (zh) 2022-03-16
AU2021323304A1 (en) 2023-03-02
WO2022028547A1 (zh) 2022-02-10
EP4194457A1 (en) 2023-06-14
MX2023001566A (es) 2023-04-13
US20230234936A1 (en) 2023-07-27
KR20230050375A (ko) 2023-04-14
CA3188258A1 (en) 2022-02-10
CN115244053A (zh) 2022-10-25
CN117964623A (zh) 2024-05-03
JP2023530848A (ja) 2023-07-20
TWI833104B (zh) 2024-02-21
CN115244053B (zh) 2024-01-30

Similar Documents

Publication Publication Date Title
BR112023002112A2 (pt) Composto para direcionar e degradar proteínas, e método para preparar o mesmo e uso do mesmo
BR112022003184A2 (pt) Inibidores de pirazolo[3,4-b]pirazina shp2 fosfatase
Chen et al. Transient receptor potential vanilloid 4 ion channel functions as a pruriceptor in epidermal keratinocytes to evoke histaminergic itch
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112021022796A2 (pt) Inibidores de inflamassoma de nlrp3
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
BR112019009529A2 (pt) novos derivados de quinolina
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
UY37656A (es) Compuestos que inhiben la proteína mcl-1
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EP4292662A3 (en) Substituted indole mcl-1 inhibitors
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112022010561A2 (pt) Compostos poli-heterocíclicos como inibidores de mettl3
BR112022007710A2 (pt) Composições farmacêuticas de albumina e rapamicina
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112018074381A2 (pt) [8-(fenil sulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il] (1h-1,2,3-triazol-4-il)metanonas
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
BR112022001628A2 (pt) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
BR112018072468A2 (pt) composto para uso como um inibidor de quinase, composto ou n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero, método in vitro para inibir atividade de proteína quinase e composição farmacêutica